Melanoma New Zealand

The Quality Statements where developed by experts in the field and funded by the Ministry of Health. The aim of the statements is to improve melanoma care in NZ.

The Melanoma and Skin Cancer Trials Group (MASC). coordinates and conducts quality research for melanoma and skin cancer with researchers and health care professionals, support networks and consumers.

The Health Promotion Agency (HPA) is a New Zealand crown agency that promotes good health and encourages healthy lifestyles. The long-term focus of the HPA is on reducing the social, financial and health sector costs of smoking, skin cancer, problem gambling, and obesity. The prevention of skin cancer and the promotion of sun safety in New Zealand is lead by the HPA and the Cancer Society of New Zealand.

The overarching objective of Cancer Trials New Zealand (CTNZ) is to contribute to the ‘New Zealand Cancer Control Strategy’ commitment to improve cancer control through research.

Established in 2003, Cancer Trials New Zealand was developed to assist clinical researchers and the existing Cancer research units by creating an adaptive infrastructure to facilitate more rapid development of new ideas from investigators across all disciplines.

The primary focus of the group is on encouraging and supporting investigator initiated phase I and II oncology trials. As the capacity of the trial centre increases, it will encourage more early phase / translational projects in collaboration with the New Zealand and international biotechnology and pharmaceutical industry. The group is also exploring linkages with initiatives such as rare tumour registries, pathology repositories, and national clinical databases.

Establishment of the basic structure of Cancer Trials New Zealand was made possible by a three-year foundation seeding grant from the Auckland Cancer Society.

It’s their mission to improve health and other outcomes for New Zealand by providing a national resource to facilitate clinical trials research in cancer